Literature DB >> 18560908

Invasive group B streptococcus (GBS) disease in Norway 1996-2006.

H Bergseng1, M Rygg, L Bevanger, K Bergh.   

Abstract

The aim of this study was to survey the occurrence of invasive group B streptococcus (GBS) disease in Norway and detect possible trends in characteristics of invasive GBS strains from 1996 to 2006. Data from national monitoring systems for infectious diseases in Norway were analysed. Of 638,452 live births in the period, 434 cases of invasive GBS disease in infants were reported. In adults and children older than 1 year of age, 969 cases were reported. The incidence of invasive GBS disease increased significantly in the elderly, while the incidence of neonatal early-onset disease was stable with 0.46 cases per 1,000 live births. The incidence of late-onset disease increased in 2005 and 2006. The lethality of GBS in infants increased from an average of 6.5% in 1996-2005 to 20% in 2006. Serotypes III and V were predominant in 839 invasive GBS strains characterized-type III in infants and type V in the elderly. The distribution of serotypes did not change throughout the period. The distribution of detected surface proteins was stable from 1996 to 2005, but the detection rates in types III and V were low. Molecular methods for GBS typing introduced in 2006 made characterization of nearly all strains possible and appear more applicable to epidemiological studies of GBS than conventional methods. Resistance to erythromycin and clindamycin increased significantly in 2006. The increased incidence in the elderly, the increased lethality in infants in 2006, and the increased resistance to erythromycin and clindamycin the same year might indicate changing characteristics of invasive GBS strains.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18560908     DOI: 10.1007/s10096-008-0565-8

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  36 in total

1.  Estimated early-onset group B streptococcal neonatal disease.

Authors:  Suzanne Luck; Michael Torny; Katrina d'Agapeyeff; Alison Pitt; Paul Heath; Aoadhan Breathnach; Alison Bedford Russell
Journal:  Lancet       Date:  2003-06-07       Impact factor: 79.321

2.  Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis.

Authors:  S J Schrag; S Zywicki; M M Farley; A L Reingold; L H Harrison; L B Lefkowitz; J L Hadler; R Danila; P R Cieslak; A Schuchat
Journal:  N Engl J Med       Date:  2000-01-06       Impact factor: 91.245

3.  Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults.

Authors:  Carol J Baker; Marcia A Rench; Lawrence C Paoletti; Morven S Edwards
Journal:  Vaccine       Date:  2006-07-31       Impact factor: 3.641

4.  Type classification of group B streptococci by the fluorescent antibody test.

Authors:  L Bevanger; J A Maeland
Journal:  Acta Pathol Microbiol Scand B       Date:  1977-12

5.  Type-specific polysaccharide antigens of group B streptococci.

Authors:  R C Lancefield; E H Freimer
Journal:  J Hyg (Lond)       Date:  1966-06

6.  A Streptococcus agalactiae R protein analysed by polyclonal and monoclonal antibodies.

Authors:  L Bevanger; A I Kvam; J A Maeland
Journal:  APMIS       Date:  1995-10       Impact factor: 3.205

7.  Group B streptococcus bacteremia in nonpregnant adults.

Authors:  P Muñoz; A Llancaqueo; M Rodríguez-Créixems; T Peláez; L Martin; E Bouza
Journal:  Arch Intern Med       Date:  1997-01-27

8.  Serotype identification of group B streptococci by PCR and sequencing.

Authors:  Fanrong Kong; Sonia Gowan; Diana Martin; Gregory James; Gwendolyn L Gilbert
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

Review 9.  Group B streptococcal infections in elderly adults.

Authors:  Morven S Edwards; Carol J Baker
Journal:  Clin Infect Dis       Date:  2005-08-16       Impact factor: 9.079

10.  Comparison of DNA dot blot hybridization and lancefield capillary precipitin methods for group B streptococcal capsular typing.

Authors:  Stephanie M Borchardt; Betsy Foxman; Donald O Chaffin; Craig E Rubens; Patricia A Tallman; Shannon D Manning; Carol J Baker; Carl F Marrs
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

View more
  20 in total

Review 1.  Prevention of group B streptococcal neonatal disease revisited. The DEVANI European project.

Authors:  J Rodriguez-Granger; J C Alvargonzalez; A Berardi; R Berner; M Kunze; M Hufnagel; P Melin; A Decheva; G Orefici; C Poyart; J Telford; A Efstratiou; M Killian; P Krizova; L Baldassarri; B Spellerberg; A Puertas; M Rosa-Fraile
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-09       Impact factor: 3.267

2.  Characterisation of invasive group B streptococci from adults in Denmark 1999 to 2004.

Authors:  L Lambertsen; K Ekelund; I C Skovsted; A Liboriussen; H-C Slotved
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-07-31       Impact factor: 3.267

3.  Dominance of serotype Ia among group B Streptococci causing invasive infections in nonpregnant adults in Portugal.

Authors:  E R Martins; J Melo-Cristino; M Ramirez
Journal:  J Clin Microbiol       Date:  2012-01-04       Impact factor: 5.948

4.  Genomic analysis reveals the molecular basis for capsule loss in the group B Streptococcus population.

Authors:  Roberto Rosini; Edmondo Campisi; Matteo De Chiara; Hervé Tettelin; Daniela Rinaudo; Chiara Toniolo; Matteo Metruccio; Silvia Guidotti; Uffe B Skov Sørensen; Mogens Kilian; Mario Ramirez; Robert Janulczyk; Claudio Donati; Guido Grandi; Immaculada Margarit
Journal:  PLoS One       Date:  2015-05-06       Impact factor: 3.240

5.  Group B streptococci causing neonatal infections in barcelona are a stable clonal population: 18-year surveillance.

Authors:  E R Martins; A Andreu; P Correia; T Juncosa; J Bosch; M Ramirez; J Melo-Cristino
Journal:  J Clin Microbiol       Date:  2011-06-22       Impact factor: 5.948

6.  Molecular epidemiology of group B streptococci in Ireland reveals a diverse population with evidence of capsular switching.

Authors:  Mary Meehan; Robert Cunney; Mary Cafferkey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-28       Impact factor: 3.267

Review 7.  Group B Streptococcus vaccine: state of the art.

Authors:  Annalisa Nuccitelli; C Daniela Rinaudo; Domenico Maione
Journal:  Ther Adv Vaccines       Date:  2015-05

Review 8.  Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.

Authors:  Miwako Kobayashi; Johan Vekemans; Carol J Baker; Adam J Ratner; Kirsty Le Doare; Stephanie J Schrag
Journal:  F1000Res       Date:  2016-09-22

9.  CRISPR Typing Increases the Discriminatory Power of Streptococcus agalactiae Typing Methods.

Authors:  Clémence Beauruelle; Ludovic Treluyer; Adeline Pastuszka; Thierry Cochard; Clément Lier; Laurent Mereghetti; Philippe Glaser; Claire Poyart; Philippe Lanotte
Journal:  Front Microbiol       Date:  2021-07-19       Impact factor: 5.640

10.  Implementation of a cost-effective strategy to prevent neonatal early-onset group B haemolytic streptococcus disease in the Netherlands.

Authors:  Diny G E Kolkman; Marlies E B Rijnders; Maurice G A J Wouters; M Elske van den Akker-van Marle; Cpb Kitty van der Ploeg; Christianne J M de Groot; Margot A H Fleuren
Journal:  BMC Pregnancy Childbirth       Date:  2013-07-30       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.